Navigation Links
Unilife Corporation Announces Financial Results For Fiscal Year 2013 First Quarter
Date:11/8/2012

YORK, Pa., Nov. 8, 2012 /PRNewswire/ -- Unilife Corporation ("Unilife" or "Company") (NASDAQ: UNIS; ASX: UNS) today announced financial results for the quarter ended September 30, 2012, (the first quarter of Fiscal Year 2013).

Recent Highlights:

  • The continued expansion of the Unilife proprietary portfolio of innovative, differentiated device technologies with the addition of the LISA Reusable Auto-Injector, the Unilife Depot-Ject™ platform for implanting a drug depot and the Unilife Ocu-Ject™ platform for the injection of microliter sized doses.
  • The scheduled expansion of the commercial development team with several additional key hires that strengthen the position of Unilife to serve the unmet and emerging needs of a growing network of new and prospective pharmaceutical and biotechnology customers.
  • Mr. Alan Shortall, CEO of Unilife, said, "All fundamental areas of the Unilife business remain fully on track. Our commercial pipeline continues to strengthen in both size and scope. Discussions are advancing favorably with a significant number of pharmaceutical customers, many of whom are targeting at least one of our devices for use with several of their injectable therapies. The recent expansion of our commercial development team and strong exhibition at the PDA Universe of Prefilled Syringes Conference in Las Vegas should help to underline the favorable market perception Unilife continues to generate across the pharmaceutical market for injectable drug delivery systems.

    "With many negotiations regarding commercial supply contracts and clinical development agreements now at an advanced status, we look forward to generating attractive, incremental and long-term revenue streams. I expect shareholders should have reason to be pleased with our flow of agreements throughout Fiscal Year 2013 and beyond," Mr. Shortall concluded.

    Financial Results for Three Months Ended September 30, 2012 Revenues for the three months ended September 30, 2012 were $0.7 million compared to $2.1 million for the same period in 2011. During the three months ended September 30, 2011, the Company recognized revenue of $1.4 million related to the completion of the final milestone under its industrialization program with Sanofi. The Company's net loss for the three months ended September 30, 2012 was $12.5 million, or $0.16 per share, compared to a net loss of $9.7 million, or $0.16 per share, for the same period in 2011. The increase in the net loss was primarily attributable to the decrease in revenue and an increase in research and development expenses related to the development of the Company's portfolio of injectable drug delivery systems.

    Adjusted net loss for the three months ended September 30, 2012 was $9.1 million, or $0.12 per share, compared to $6.5 million, or $0.11 per share, for the same period in 2011. Adjusted net loss excludes non-cash share-based compensation expense, depreciation and amortization and interest expense. Unilife had $20.9 million of total cash, including restricted cash, as of September 30, 2012.Conference Call InformationManagement has scheduled a conference call for 4:30 p.m. U.S. EST on Thursday, November 8, 2012 (Friday, November 9, 2012 at 8:30 a.m. AEDT), to review the Company's financial results, market trends and future outlook.  The conference call and accompanying slide presentation will be broadcast over the Internet as a "live" listen only Webcast.  An archive of the presentation and webcast will be available for 30 days after the call.  To listen, please go to: http://ir.unilife.com/events.cfm.

    About Unilife CorporationUnilife Corporation (NASDAQ: UNIS / ASX: UNS) is a U.S. based developer and commercial supplier of injectable drug delivery systems. Unilife collaborates with pharmaceutical and biotechnology companies seeking innovative, differentiated devices that can enable or enhance the delivery of injectable drugs and vaccines supplied in either a liquid stable or lyophilized form. The Unifill syringe, the world's first and only prefilled syringe with fully integrated safety features, sits at the leading edge of this diversified portfolio. In addition to prefilled and hypodermic safety syringes with automatic, user-controlled needle retraction, Unilife has other proprietary technology platforms including drug reconstitution delivery systems, auto-injectors, auto-infusion pump systems and specialized devices for targeted organ delivery. Unilife's global headquarters and state-of-the-art manufacturing facilities are located in York, PA. For more information on Unilife, please visit www.unilife.comForward-Looking Statements This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our Annual Report on Form 10-K and those described from time to time in other reports which we file with the Securities and Exchange Commission. 

    Non-GAAP Financial MeasuresU.S. securities laws require that when we publish any non-GAAP financial measure, we disclose the reason for using the non-GAAP measure and provide reconciliation to the most directly comparable GAAP measure.  The presentation of adjusted net income (loss) and adjusted net income (loss) per share are non-GAAP measures.  Adjusted net income (loss) represents net income (loss) calculated in accordance with U.S. GAAP as adjusted for the impact of share-based compensation expense, depreciation and amortization and interest expense.

    Management believes the presentation of adjusted net income (loss) and adjusted net income (loss) per share provides useful information because these measures enhance its own evaluation, as well as investor's understanding, of the Company's core operating and financial results.  Non-GAAP financial measures should be considered in addition to results prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, GAAP results.  A reconciliation of net income (loss) to adjusted net income (loss) is included in the attached table.

    General: UNIS-G Investor Contacts (US):
    Analyst EnquiriesInvestor Contacts (Australia)Todd Fromer / Garth RussellLynn PieperJeff CarterKCSA Strategic CommunicationsWestwicke PartnersUnilife CorporationP: + 1 212-682-63P: + 1 415-202-5678P: + 61 2 8346 6500 

    (Tables Below)

     

     

     

    UNILIFE CORPORATION AND SUBSIDIARIESConsolidated Balance Sheets(unaudited)September 30, 2012June 30, 2012(in thousands, except share data)Assets  Current Assets:  Cash and cash equivalents

    $
    8,458$
    ,410  Restricted cash

    2,4002,400  Accounts receivable

    1,1111,042  Inventories

    207212  Prepaid expenses and other current assets

    463676Total current assets

    22,63915,740Property, plant and equipment, net

    51,56852,514Goodwill

    13,00212,734Intangible assets, net

    3334Other assets

    1,2801,286Total assets

    $
    88,522$
    82,308Liabilities and Stockholders' EquityCurrent Liabilities:  Accounts payable

    $
    2,198$
    2,399  Accrued expenses

    2,2312,209  Current portion of long-term debt

    6,7295,655  Deferred revenue

    2,6512,595Total current liabilities

    13,80912,858Long-term debt, less current portion

    20,91923,110Deferred revenue

    2,0382,595Total liabilities

    36,76638,563Stockholders' Equity:  Preferred stock, $0.01 par value, 50,000,000 sharesauthorized as of September 30, 2012; 


    none issued or outstanding as of September 30,
    2012 and June 30, 2012

    --  Common stock, $0.01 par value, 250,000,000 sharesauthorized as of September 30, 2012; 


    81,844,749 and 75,849,439 shares issued, and
    81,816,079 and 75,820,769 shares outstanding as of September 30, 2012 and June 30, 2012,respectively

    818758Additional paid-in-capital

    232,601212,326Accumulated deficit

    (185,131)(172,634)Accumulated other comprehensive income

    3,6083,435Treasury stock, at cost, 28,670 and 28,670 shares as of September 30, 2012 and June 30, 2012,

    respectively

    (140)(140)Total stockholders' equity

    51,75643,745Total liabilities and stockholders' equity

    $
    88,522$
    82,308UNILIFE CORPORATION AND SUBSIDIARIESConsolidated Statements of Operations(unaudited)Three Months Ended
    September 30,20122011(in thousands, except per share data)Revenues:  Industrialization and development fees

    $
    -$
    ,440  Licensing fees

    663672  Product sales and other

    2918Total revenues

    6922,130Cost of product sales

    5974  Gross profit

    6332,056Operating expenses:  Research and development

    4,7384,298  Selling, general and administrative

    6,5776,183  Depreciation and amortization

    1,223993  Total operating expenses

    12,53811,474Operating loss

    (11,905)(9,418)Interest expense

    616283Interest income

    (24)(30)Other expense, net

    -34Net loss

    $
    (12,497)$
    (9,705)Net loss per share:Basic and diluted net loss per share

    $
    (0.16)$
    (0.16) 

    UNILIFE CORPORATION AND SUBSIDIARIESReconciliation of Non-GAAP Measure(unaudited)Three Months Ended
    September 30,20122011(in thousands, except per share data)Net loss

    $
    (12,497)$
    (9,705)Share-based compensation expense

    1,5551,900Depreciation and amortization

    1,223993Interest expense

    616283Adjusted net loss

    $
    (9,103)$
    (6,529)Adjusted net loss per share - diluted

    $
    (0.12)$
    (0.11) 


    '/>"/>
    SOURCE Unilife Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Unilife Signs Long-Term Supply Contract for the Unifill Prefilled Syringe
    2. Unilife Granted Key U.S. Patent for Unifill Prefilled Syringe
    3. Unilife Corporation to Announce Financial Results for Fiscal 2012 Fourth Quarter and Year End on Monday, July 30, 2012
    4. Unilife Corporation Announces Financial Results For Fiscal Year 2012 Fourth Quarter
    5. Griffin Securities Analyst Interviews Unilife Corp. CEO in a Two-Part Video Series
    6. Unilife Corporation To Announce Financial Results For Fiscal 2013 First Quarter On Tuesday, October 30, 2012
    7. Second Part of the Griffin Securities Analyst Interview with Unilife Corp. CEO is Now Available
    8. Unilife Corporation Reschedules Release Of Quarterly Results And Earnings Call Due To Severe Weather In Northeastern U.S.
    9. Unilifes Bolus Injector Platform Targeted by Global Pharmaceutical Company for Use in Multi-Drug Program
    10. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
    11. CVS Caremark Corporation to Hold First Quarter 2012 Conference Call
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/2/2016)... , December 2, 2016 According ... titled "Global Market Study on Automated Endoscope Reprocessors: Single Basin ... CAGR of 8.6% Between 2016 and 2024 " the global automated endoscope ... is expected to expand at a CAGR of 7.2% during ... of US$ 1,367.6 Mn by 2024. ...
    (Date:12/2/2016)... ATLANTA , Dec. 2, 2016 Quantum ... screening and expert radiologist interpretation directly to women at ... partners with corporations, such as Delta Air Lines and ... cancer screening as a component of wellness initiatives. ... women of SunTrust. It enables them to have a ...
    (Date:12/2/2016)... , December 2, 2016 ... Awards Committee honored excellence in research, development and innovation ... The gala dinner was held in the presence of ... the Russian Federation , Natalia Sanina, ... Mikhail Murashko , Head of Roszdravnadzor, National Service ...
    Breaking Medicine Technology:
    (Date:12/2/2016)... ... December 02, 2016 , ... U.S. Surgeon General, Dr. Vivek ... Dr. Murthy explains how he was inspired to practice medicine at an early age ... is about more than making diagnoses and prescribing medicine,” he states. “It is about ...
    (Date:12/2/2016)... ... December 02, 2016 , ... Dr. Raffi Hovsepian, a leading ... the 2016 “Guide to America’s Top Plastic Surgeons” for seven consecutive years. The ... education, experience, and professional associations. , One the most frequently honored surgeons ...
    (Date:12/2/2016)... ... December 02, 2016 , ... ... of its SaaS LIMS, CloudLIMS Lite. CloudLIMS Lite helps biobanks, clinical, research and ... storing, shipping and disposal. The new version is a faster and a more ...
    (Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... Sourced from ... has some unique properties including its unmatched natural purity of just 6 ppm TDS ... and crisp. , Nothing Water has been available in several ShopRite and FoodTown stores ...
    (Date:12/2/2016)... ... December 02, 2016 , ... "Pro3rd Accents Volume 2 is ... create versatile lower third titles with just a few clicks of the mouse," said ... includes 30 lower third animations. Choose from various styles with accented animations, rigid boxes, ...
    Breaking Medicine News(10 mins):